Evidence map›Paper›PMID 24454372›Full record

ArticleJournal of oncology2013

Serum p53 Antibody Is Not Associated with p53 Immunoreactivity in Patients with Pancreatobiliary Cancers.

Junko Umeda, Takao Itoi, Atsushi Sofuni, Fumihide Itokawa, Toshio Kurihara, Takayoshi Tsuchiya, Kentaro Ishii, Shujiro Tsuji, Nobuhito Ikeuchi, Reina Tanaka and 6 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of oncology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 5 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Junko UmedaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Takao ItoiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Atsushi SofuniDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Fumihide ItokawaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Toshio KuriharaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Takayoshi TsuchiyaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Kentaro IshiiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Shujiro TsujiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Nobuhito IkeuchiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Reina TanakaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Ryosuke TonozukaDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Mitsuyoshi HonjoDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Shuntaro MukaiDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Toshitaka NagaoDepartment of Pathology, Tokyo Medical University, Tokyo 160-0023, Japan.
Hisashi OshiroDepartment of Pathology, Tokyo Medical University, Tokyo 160-0023, Japan.
Fuminori MoriyasuDepartment of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo 160-0023, Japan.
Tokyo Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background. Recent diagnostic imaging tests contribute to improving the diagnosis of pancreatobiliary cancers. However, it is not practical to perform these tests for all patients as screening. Thus, less-invasive and simple screening tests are still required. A method to detect the IgG antibody induced in serum against the p53 protein accumulating due to p53 gene mutation, as a biomarker, was developed around 1990. Method. 35 patients with pancreatic cancer, 12 patients with biliary tract cancer, and 31 patients with benign pancreatobiliary diseases were entered into this study. Measurement of serum anti-p53 antibody was conducted in all patients. In addition, the rate of p53 protein overexpression was examined in those cases that could be examined pathologically. Result. Among all patients in the pancreatic cancer and biliary tract cancer groups, there was no patient with serum anti-p53 antibody positive value that exceeded the standard value. The rate of p53 protein overexpression was 48.0% in the patients with pancreatobiliary cancers and 0% in the benign pancreatobiliary diseases group. Conclusion. Serum anti-p53 antibody measurement does not contribute to the diagnosis of pancreatobiliary cancers. Instead, traditional p53 immunostaining still appears to be valuable in combination with standard procedures.

Identifiers

PMID24454372
PMCPMC3880693
OpenAlexW2040905181

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.